Does Retatrutide Cause Burning Skin, Numbness or Tingling?

What do the retatrutide trial tables actually list for skin sensations?

The retatrutide phase 2 results list allodynia and hyperaesthesia across separately assigned study arms, with allodynia recorded only in the highest arm. The adverse-event record covers 338 participants over 52 weeks, and every arm below was given as a once-weekly subcutaneous injection. Counts below are participants with the named event divided by participants in that arm; the registry identifiers distinguish groups sharing a nominal dose. [NCT04881760]

These are the study arms of the cited trials, not an application protocol for research vials.

The registry's reporting threshold for other, nonserious adverse events was 5% in any group. In the ClinicalTrials.gov search retatrutide, checked 13 September 2026, NCT04881760 had no Dysaesthesia or Paraesthesia row. That omission is a reporting gap, not a reported zero: events below the threshold can be absent from the displayed terms. [NCT04881760, adverse-event module]

Laroche's review summarized skin sensitivity and hyperesthesia as about 7% across retatrutide participants versus 1% with placebo over 48 weeks, describing the events as mild to moderate without treatment discontinuation. That pooled summary and the registry's individual event rows are different presentations of the same trial, not independent confirmations. [PMID 42168638]

Why do "burning", "numbness" and "tingling" carry different names in the tables?

Dysaesthesia is an umbrella term for altered skin sensations, while source tables can separate the component sensations or combine them. The review includes reduced sensation, heightened sensitivity, paraesthesia and burning within that broader description. A search for the umbrella word alone therefore misses relevant terminology. [PMID 42168638]

For the approved medicine Wegovy in patients, the label's composite includes allodynia, burning sensation, hyperesthesia, paresthesia, sensitive skin and other terms. This is semaglutide class evidence, not a definition of the retatrutide registry rows. [Wegovy label, section 6.1, footnote a]

The pharmacovigilance review likewise found reports under paraesthesia, hypoaesthesia and burning sensation, alongside dysaesthesia. Its methods excluded administration-site reactions from the sensory-event analysis. These reports describe reported events rather than a trial denominator. Local burning belongs to the separate injection-site reactions page. [PMID 42168638]

What do the approved tirzepatide labels report?

The labels for the approved medicines Zepbound and Mounjaro report dysesthesia in patients, with different frequencies in their respective trial pools. PeptidesDirect does not sell tirzepatide.

These are the study arms of the cited trials, not an application protocol for research vials.

For approved Zepbound in patients, the label reports 0.2% in the 5 mg arm, 0.2% in the 10 mg arm and 0.4% in the 15 mg arm, versus 0.1% with placebo; these are once-weekly subcutaneous study arms. For approved Mounjaro in patients, the label reports 0.4% in each corresponding arm, with no events reported by placebo participants. These are source-reported comparator findings. [Zepbound and Mounjaro labels, sections 2 and 6.1, 02 September 2026]

Separately, SURMOUNT-J recorded dysaesthesia, paraesthesia and hypoaesthesia each in 1/73 participants in the once-weekly subcutaneous tirzepatide 10 mg arm and 1/77 in the 15 mg arm, versus 0/75 with placebo over 76 weeks. Its reporting threshold was 0, unlike the retatrutide record. The different reporting rules matter when comparing the visible event lists. [NCT04844918]

How does the semaglutide class picture compare?

The approved medicine Wegovy's patient trial tables show that dysesthesia frequencies differ between datasets; these semaglutide figures are class evidence, not retatrutide rates. [Wegovy label, section 6.1]

PeptidesDirect does not sell semaglutide.

These are the study arms of the cited trials, not an application protocol for research vials.

As semaglutide class evidence, the approved Wegovy label reports patient trial rates of 6% in the 2.4 mg arm and 22% in the 7.2 mg arm, versus 0% with placebo; a separate comparison reports 1% in the 2.4 mg arm versus 2% with placebo. These are once-weekly subcutaneous study arms, and each comparison carries its own placebo group. [Wegovy label, sections 2 and 6.1]

Also as semaglutide class evidence, the approved Wegovy label reports that 18% of affected patients did not report recovery during the trial, and 17 of 38 patients (45%) reported recurrence of dysesthesia on re-escalation to 7.2 mg. Those observations describe the trial course, not a management instruction or a retatrutide duration estimate. [Wegovy label, section 6.1]

What is still unknown for retatrutide?

Retatrutide-specific characterization remains limited: the PubMed search retatrutide AND (dysesthesia OR dysaesthesia OR hyperesthesia OR paresthesia OR skin sensitivity), checked 13 September 2026, returned 1 hit, the review, rather than a primary publication characterizing these events beyond the trial findings. The review described the underlying mechanism as unknown. [PMID 42168638]

The ClinicalTrials.gov v2 search retatrutide, checked 13 September 2026, returned 34 studies, with posted results only for NCT04881760 and NCT04867785, both phase 2. NCT05931367 had no posted results. Retatrutide remains investigational; approved-medicine label frequencies cannot be assigned to it. Gastrointestinal duration is covered separately in the nausea and stomach-effects page.

Products mentioned

Retatrutidemetabolic

Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide that acts on three receptors at once: GLP-1, GIP and glucagon. Supplied as a lyophilized powder for in-vitro research, with a batch-specific third-party certificate of analysis.

Sources

1. ClinicalTrials.gov. Retatrutide phase 2 results and adverse-event module. NCT04881760. Search checked 13 September 2026.
2. ClinicalTrials.gov. SURMOUNT-J results. NCT04844918.
3. DailyMed. 02 September 2026. Zepbound label, sections 2 and 6.1. Setid 487cd7e7-434c-4925-99fa-aa80b1cc776b.
4. DailyMed. 02 September 2026. Mounjaro label, sections 2 and 6.1. Setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0.
5. DailyMed. 30 June 2026. Wegovy label, section 2, section 6.1 and footnote a. Setid ee06186f-2aa3-4990-a760-757579d8f77b.
6. Laroche. 2026. Review, discussion and pharmacovigilance analysis. PMID 42168638 / PMC13194321.
7. ClinicalTrials.gov. Retatrutide search, 13 September 2026. NCT04867785; NCT05931367.

Research use only. Every compound sold here is supplied strictly for in-vitro research. Nothing on this page is a protocol, a recommendation or medical advice.